Cabergoline

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 3, 2000, Pages 555-574

  Colao, Annamaria ^a   Lombardi, Gaetano ^a   Annunziato, Lucio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acromegaly; Bromocriptine; Cabergoline; Dopamine agonists; Growth hormone; Hyperprolactinaemia; Prolactin

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE;

ANIMAL; ARTICLE; FEMALE; HUMAN; HYPERPROLACTINEMIA; PREGNANCY;

ANIMALS; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; PREGNANCY;

EID: 0034157480     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.3.555     Document Type: Review

References (139)

1. LEMBERGER L: The pharmacology of ergots: past and present. Fed. Proc. (1978) 37:2176-2180.
2. MANTEGANI S, BRAMBILLA E, VARASI M: Ergoline derivatives: receptor affinity and selectivity. Il Farmaco. (1999) 54:288-296.
3. BRAMBILLA E, DI SALLE E, BRIATICO G, MANTEGANI S, TEMPERILLI A: Synthesis and nidation inhibitory activity of a new class of ergoline derivatives. Eur. J. Med. Chem. (1989) 24:421-426.
4. DI SALLE E, ORNATI G, BRIATICO G: FCE 21336, a new ergoline derivative with a potent and long-acting lowering effect on prolactin secretion in rats. J. Endocrinol. Invest. (1982) 45.
5. VANCE ML, THORNER MO: Prolactin: hyperprolactinemic syndromes and management. In: Textbook of Endocrinology (2nd Edition) DeGroot LJ (Ed.), WB Saunders Co., Philadelphia, USA (1989):408-418.
6. HO KY. THORNER MO: Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs (1988) 36:67-82.
7. RAINS CP, BRYSON HM, FITTON A: Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs (1995) 49:255-279.
8. 3H] N-n-propylnorapomorphine. Eur. J. Pharmacol. (1990) 187:399-408.
9. BEVAN JS, WEBSTER J, BURKE CW et al.: Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. (1992) 13:220-240. A very comprehensive and accurate review on the effects of DAs on tumour volume addressing the molecular basis for their shrinking effect.
10. ENJALBERT A, BOCKAERT J: Pharmacological characterisation of the D-2 dopamine receptor negatively coupled with adenylated cyclase in rat anterior pituitary. Mol. Pharmacol. (1983) 23:576-584.
11. SPADA A, NICOSIA S, CORTELLAZZI L et al.: In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide. J. Clin. Endocrinol. Metab. (1983) 56:1-10.
12. 2-dopamine receptors. Mol. Cell. Endocrinol. (1984) 36:201-209.
13. CROSIGNANI PG, FERRARI C: Dopaminergic treatments forhyperprolactinemia. Baillieres Clin. Obstet. Gynaecol. (1990) 4:441-455.
14. TROUILLAS J, CHEVALLIER P, CLAUSTRAT B et al.: Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat. Endocrinology (1994) 134:401-410.
15. EGUCHI K, KAWAMOTO K, UOZUMI T, ITO A, ARITA K, KURISU K: In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors. Endocr. J. (1995) 42:153-161.
16. EGUCHI K, KAWAMOTO K, UOZUMI T, ITO A, ARITA K, KURISU K: Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies. Endocr. J. (1995) 42:413-420.
17. JOCHLE W, ARBEITER K, POST K et al.: Effects on pseudo-pregnancy, pregnancy and interoestrous intervals of pharmacological suppression of prolactin secretion in female dogs and cats. J. Reprod. Fertil. (1989) 39(Suppl.):199-207.
18. VESTERGEN JP, ONCLIN K, SILVA LD et al.: Abortion induction in the cat using prostaglandin F2 alpha and a new anti-prolactinic agent cabergoline. J. Reprod. Fertil. (1993) 47(Suppl.):411-417.
19. POOTIROLI AE, VIBERTI GC, MANGILI R et al.: Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3′-dimethylaminopropyl)-3-(6′ allylcrgoline-8′-b-carbonyl)urea-diphosphate (FCE 21336). Br. J. Clin. Pharmacol. (1987) 23:433-438.
20. ANDREOTTI AC, PIANEZZOLA E, PERSIANI S et al.: Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. J. Clin. Endocrinol. Metab. (1995) 80:841-845.
21. MELIS GB, GAMBACCIANI M, PAOLETTI AM et al.: Dose related prolactin-inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal and hyperprolactinemic women. J. Clin. Endocrinol. Metab. (1987) 65:541-545.
22. DISALLE E, ORNATI G, GIUDICI D et al.: Effect of the new ergoline derivative FCE 21336 on prolactin and LH secretion in the rat. J. Endocrinol. Invest. (1983) 6(Suppl. 1):6.
23. FERRARI C, MATTEI A, MELIS GB et al.: Cabcrgoline: long-acting oral treatment of hyperprolactinemic disorders. J. Clin. Endocrinol. Metab. (1989) 68:1201-1206.
24. FERRARI C, PARACCHI A, MATTEI AM et al.: Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (1992) 126:489-494.
25. FALSETTI L, ZANAGNOLO V, GALBIGIANI E: Cabergoline treatment in hyperprolactinemic women. J. Obstet. Gynecol. (1991) 11:68-71.
26. GIUSTI M, LOMEO A, TORRE R et al.: Effect of subacute cabergoline treatment on prolactin, thyroid stimulating hormone and growth hormone response to simultaneous administration of thyrotropin-releasing hormone and growth hormone-releasing hormone in hyperprolactinemic women. Clin. Endocrinol. (1989) 30:315-321.
27. DURANTE R, GIUSTI M, CARRARO A et al.: LHRH-induced gonadotropin release before and after short-term therapy with cabergoline in hyperprolactinemic patients. Minerva Endocrinol. (1991) 16:11-16.
28. DALL'ARA A, LIMA L, COCCHID et al.: Inhibitory effect of cabergoline on the development of oestrogen-induced prolactin-secreting adenomas of the pituitary. Eur. J. Pharmacol. (1988) 151:97-102.
29. GIUDICI D, ZACCHEO T, ORNATI G et al.: Antitumour activity of FCE 21336, a new prolactin lowering drug, on experimental hormone-responsive tumors. J. Steroid. Biochem. Mol. Biol. (1983) 19(Suppl.):145S.
30. FORNELLI F, ZACCHEO T, DI SALLE E et al.: Correlation between inhibitory effect on prolactin secretion and anti-tumour activity of new ergoline compounds on DMBA-induced tumours in rats. Eur. J. Cancer.Clin. Oncol. (1983) 19:1545-1551.
31. PERSIANI S, PIANEZZOLA E, BROUTIN F et al.: Radioimmunoassay for the synthetic ergoline derivative cabergoline in biological fluids. J. Immunoassay (1992) 13:457-476.
32. PIANEZZOLA E, BELLOTTI V, LA CROIX R et al.: Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. (1992) 574:170-174.
33. 3H] cabergoline in man. Drug Metab. Drug Interact. (1992) 10:199-211.
34. BATTAGLIA R, STROLIN BENEDETTI M et al.: Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man. Xenobiotica (1993) 23:1377-1389.
35. COLAO A, LOMBARDI G: Growth hormone and prolactin excess. Lancet (1998) 352:1455-1461. An up-to-date review on the most relevant clinical issues of GH and PRL excess.
36. DELGRANGE E, MAITER D, DONCKIER J, TOURNIAIRE J: Influence of age on the clinical presentation of prolactinomas in male patients. Gerontology (1999) 45:160-164.
37. LEVY A, LIGHTMAN SL: Diagnosis and management of pituitary tumors. Br. Med. J. (1994) 308:1087-1091.
38. DALKIN AC, MARSHALL JC: Medical therapy of hyperprolactinemia. Endocrinol. Metab. Clin. North Am. (1989) 18:259-276.
39. CUNNAH D, BESSER M: Management of prolactinomas. Clin. Endocrinol. (1991) 34:231-235.
40. MOLITCH ME, THORNER MO, WILSON C: Management of prolactinomas. J. Clin. Endocrinol. Metab. (1997) 82:996-1000.
41. COLAO A, ANNUNZIATO L, LOMBARDI G: Treatment of prolactinomas. Ann. Med. (1998) 30:452-459-Up-to-date reviews on the treatment strategies in hyperprolactinaemia.
42. VANCE M, EVANS W, THORNER M: Bromocriptine. Ann. Intern. Med. (1984) 100:78-91.
43. WEBSTER J: A comparative review of the tolerability profiles of DA agonists in the treatment of hyperprolactinemia and inhibition of lactation. Drug Saf. (1996) 14:228-238.
44. BRUE T, PELLEGRINI J, GUNZ G et al.: Effects of dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J. Clin. Endocrinol. Metab. (1992) 74:577-584.
45. VILAR L, BURKE CW et al.: Quinagolide efficacy and tolerability in hyperprolactinemic patients who are resistant to or intolerant of bromocriptine. Clin. Endocrinol. (1994) 41:821-826.
46. RASMUSSEN C, BROWNELL J, BERGHT T: Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. Acta Endocrinol. (1991) 125:78 -91.
47. MEROLA B, SARNACCHIARO F, COLAO A et al.: Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol. Endocrinol. (1994) 8:1-7.
48. NEWMAN CB, HURLEY AM, KLEINBERG DL et al.: Effect of CV 205-502 in hyperprolactinemic patients intolerant to bromocriptine. Clin. Endocrinol. (1989) 31:391-400.
49. CICCARELLI E, GIUSTI M, MIOLA A et al.: Effectiveness and tolerability of long-term treatment with cabergoline, a new-lasting ergoline derivative, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. (1989) 69:725-728.
50. MURATORI M, AROSIO M, GAMBINO G, ROMANO C, BIELLA O, FAGLIA G: Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J. Endocrinol. Invest. (1997) 20:537-546.
51. WEBSTER J, PISCITELLI G, POLLI A et al.: The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinemic disorders: an open, uncontrolled, multicentre study. Clin. Endocrinol. (1993) 39:323-329.
52. WEBSTER J, PISCITELLI G, POLLI A et al.: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. (.1994) 331:904-909. The first paper addressing the issue of the comparison between the efficacy of bromocriptine and cabergoline including a very large series of patients with microprolactinoma and non-tumoural hyperprolactinaemia.
53. VERHELST J, ABS R, MAITER D et al.: Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. (1999) 84:2518-2522. The most recent paper including the largest series of patients with hyperprolactinaemia treated with cabergoline.
54. BILLER BMK, MOLITCH ME, VANCE ML et al.: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. (1996) 81:2338-2343.
55. FERRARI CI, ABS R, BEVAN JS et al.: Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin. Endocrinol. (1997) 46:409-413.
56. COLAO A, DI SARNO A, LANDI ML et al.: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J. Clin. Endocrinol. Metab. (1997) 82:3574-3579-
57. CANNAVO'S, CURTO' L, SQUADRITO S et al.: A first choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J. Endocrinol. Invest. (1999) 22:354-359.
58. COLAO A, DI SARNO A, LANDI ML et al.: Macroprolactinoma shrinkage during cabergoline treatment is greater in naive than in patients pre-treated with other dopamine agonists: a prospective study in 110 patients J. Clin. Endocrinol. Metab. (2000). (In Press).
59. DE ROSA M, COLAO A, DI SARNO A et al.: Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur. J. Endocrinol. (1998) 138:286-293.
60. CICCARELLI E, GROTTOLI S, RAZZORE P et al.: Long-term treatment with cabergoline a new long-lasting ergoline derivative in idiopathic or tumorous hyperprolactinemia and outcome of drug-induced pregnancy. J Endocrinol. Invest. (1997) 20:547-551.
61. FERRARI C, PISCITELLI G, CROSIGNANI PG: Cabergoline: a new drug for the treatment of hyperprolactinaemia. Hum. Reprod. (1995) 10:1647-1652.
62. TURKALJ I, BRAUN P, KRUPP P: Surveillance of Bromocriptine in pregnancy. JAMA (1982) 247:1589-1591.
63. CORENBLUM B, DONOVAN L: The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil. Steril. (1993) 59:671-673.
64. KLIBANSKI A, NEER RM, BEITINS IZ, RIDGWAY C, ZARVAS NT, MC ARTHUR JW: Decreased bone density in amenorrheic women. N. Engl. J. Med. (1980) 303:1511-1514.
65. KLIBANSKI A, GREENSPAN SL: Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. (1986) 315:542-546.
66. JACKSON JA, KLEEREKOPER M, PARFITT M: Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism. Ann. Intent. Med. (1986) 105:543-545.
67. GREENSPAN SL, OPPENHEIM DS, KLIBANSKI A: Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. (1989) 110:526-531.
68. BEREZIN M, SHIMON I, HADANI M: Prolactinoma in 53 men: clinical characteristics and modes of treatment. J. Endocrinol. Invest. (1995) 18:436-441. Prolactinomas in men are less frequent than in women and the presentation of the clinical syndrome is partly different as demonstrated in this paper.
69. DI SOMMA C, COLAO A, DI SARNO A et al.: Bone markers and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J. Clin. Endocrinol. Metab. (1998) 83:807-813.
70. COLAO A, DI SOMMA C, LOCHE S et al.: Prolactinomas in children and adolescents: persistent bone loss after 2 years of prolactin normalization. Clin. Endocrinol. (2000). (In Press).
71. DELGRANGE E, CRABBE J, DONCKIER J: Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm. Res. (1998) 49:250-253.
72. DELGRANGE E, MAITER D, DONCKIER J: Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur. J. Endocrinol. (1996) 134:454-456.
73. COLAO A, DI SARNO A, SARNACCHIARO F et al.: Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab. (1997) 82:876-883.
74. PELLEGRINI I, RASOLONJANAHARY R, GUNZ G et al.: Resistance to bromocriptine in prolactinomas. J. Clin. Endocrinol. Metab. (1989) 69:500-509.
75. 2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology (1994) 60:314-322.
76. BARLIERI A, PELLEGRINI-BOUILLER I, CACCAVELLI I et al.: Abnormal transduction mechanisms in pituitary adenomas. Horm. Res. (1997) 47:227-234. A review on the abnormal transduction mechanisms in pituitary adenomas.
77. DURANTEAU L, CHANSON P, LAVOINNE A, HORLAIT S, LUBETSKI J, KUHN JM: Effects of new dopaminergic agonist CV 205-502 on plasma PRL levels and tumor size in BRC-resistant prolactinomas. Clin. Endocrinol. (1991) 34:25-29.
78. RAZZAQ R, O'HALLORAN DJ, BEARWELL CG, SHALET SM: The effects of CV 205-502 in patients with hyperprolactinemia intolerant and/or resistant to bromocriptine. Horm. Res. (1993) 39:218-222.
79. CANNAVO S, BARTOLONE L, BLANDINO A, SPINELLA S, GALATIOTO S, TRIMARCHI F: Shrinkage of a PRL-sccreting pituitary macroadenoma resistant to cabergoline. J. Endocrinol. Invest. (1999) 22:306-309.
80. COLAO A, LOCHE S, CAPPA M et al.: Prolactinomas in children and adolescents. Clinical presentation and long term follow-up. J. Clin. Endocrinol. Metab. (1998) 83:2777-2780.
81. DISSANEEVATE P, WARNE GL: Hyperprolactinaemia and pituitary adenomas in adolescence. J. Pediatr. Endocrinol. Metab. (1998) 11:531-541.
82. MOLITCH ME: Medical treatment of prolactinomas. Endocrinol. Metab. Clin. North. Am. (1999) 28:143-169. Up-to-date reviews on the treatment strategies in hyperprolactinaemia.
83. JHO HD, CARRAU RL, KO Y: Endoscopic pituitary surgery. In: Neurosurgical operative Atlas. Wilkins RH, Rengachary SS (Eds.), Park Ridge, Ill: American Association of Neurological Surgeons (1996) 5:1-12.
84. CAPPABIANCA P, ALFIERI A, COLAO A et al.: Endoscopic endonasal transsphenoidal approach: an addition reason in support of surgery in the management of pituitary lesions. Skull Base Surgery (1999) 9:109-117.
85. CABALLERO-GORDO A, LOPEZ-NAZARENO N, CALDERAY M et al.: Oral cabergoline-single-dose inhibition of puerperal lactation. J. Reprod. Med. (1991) 36:717-721.
86. MELIS GB, GAMBACCIANI M, PAOLETTI AM et al.: Dose related prolactin-inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal and hyperprolactinaemic women. J. Clin. Endocrinol. Metab. (1987) 65:541-545.
87. GIORDA G, DEVINCENTIIS S, MOTTA T et al.: Cabergoline versus bromocriptine in suppression of lactation after caesarean delivery. Gynecol. Obstet. Invest. (1991) 31:93-96.
88. EUROPEAN MULTICENTER STUDY GROUP FOR CABERGOLINE IN INHIBITION OF LACTATION: Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomized, double blind, multicenter study. Br. Med. J. (1991) 302:1367-1371.
89. MELIS GB, MAIS V, PAOLETTI AM et al.: Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug cabergoline. Obstet. Gynecol. (1988) 71:311-314.
90. JAFFE CA, BARKAN AL. Acromegaly: recognition and treatment. Drugs (1994) 47:425-445.
91. MELMED S, HO K, KLIBANSKI A, REICHLIN S, THORNER MO: Recent advances in pathogenesis, diagnosis and management of acromegaly. J. Clin. Endocrinol. Metab. (1995) 80:3395-3402.
92. MELMED S, DOWLING RH, FROHMAN LA et al.: Consensus statement: benefits versus risks of medical therapy for acromegaly. Am. J. Med. (1994) 97:468-473.
93. WASS JAM, THORNER MO, MORRIS DV et al.: Long-term treatment of acromegaly with bromocriptine. Br. Med. J. (1977) 1:875-878.
94. COLAO A, FERONE D, MARZULLO P et al.: Effect of different dopaminergic agents in the treatment of acromegaly. J. Clin. Endocrinol. Metab. (1997) 82:518-523.
95. ABS R, VERSHOLST J, MAITER D et al.: Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. (1998) 83:374-378.
96. COZZI R, ATTANASIO R, BARAUSSE M et al.: Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur. J. Endocrinol. (1998) 139:516-521.
97. JACKSON SN, FOWLER J, HOWLETT TA: Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin. Endocrinol. (1997) 46:745-749.
98. LAMBERTS SWJ, VAN DER LELY AJ, DE HERDER WW, HOFLAND J: Octreotide. N. Engl. J. Med. (1996) 334:246-254.
99. LAMBERTS SWJ, ZWEENS M, VERSCHOOR L, DEL POZO E: A comparison among the growth hormone lowering effect of the somatostatin analog, SMS 201-995, bromocriptine and combination of both drugs. J. Clin. Endocrinol. Metab. (1986) 63:16-19.
100. CHIODINI PG, COZZI R, DALLABONZANA D et al.: Medical treatment of acromegaly with SMS 201-995, a somatostatin analogue: a comparison with bromocriptine. J. Clin. Endocrinol. Metab. (1987) 64:447-453.
101. FLØGSTAD AK, HALSE J, GRASS P et al.: A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J. Clin. Endocrinol. Metab. (1994) 79:461-465.
102. LOMBARDI G, COLAO A, FERONE D et al.: CV 205-502 treatment in therapy-resistant acromegalic patients. Eur. J. Endocrinol. (1995) 132:559-564.
103. FREDSTORP L, KUTZ K, WERNER S: Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clin. Endocrinol. (1994) 41:103-108.
104. 2 receptor agonist cabergoline in therapy resistant acromegalic patients. Pituitary (1999) 1:115-120.
105. LAMBERTS SWJ, LIUZZI A, CHIODINI PG, VERDE S, KLIJN JGM, BIRKENHÄGER JC: The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur. J. Clin. Invest. (1982) 12:151-155.
106. LAMBERTS SWJ, KLIJN JGM, VAN VROONHOVEN CCJ, STEFANKO SZ, LIUZZI A: The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. Acta Endocrinol. (1983) 103:446-450.
107. BECK-PECCOZ P, BRUCKER-DAVIS F, PERSANI L, SMALLRIDGE RC, WEINTRAUB BD: Thyrotropin-secreting pituitary tumours. Endocr. Rev. (1996) 17:610-638.
108. KWEKKEBOOM DJ, DE JONG FH, LAMBERTS SWJ: Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine. J. Clin. Endocrinol. Metab. (1989) 68:1128-1135.
109. SACCOMANNO K, GIL-DEL-ALAMO P, BASSETTI M, REZA-ELAHI F, SPADA A: In vitro detection of glycoprotein production and secretion by human nonfunctioning pituitary adenomas. J. Endocrinol. Invest. (1993) 16:109-115.
110. BEVAN JS, BURKE CW: Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin. Endocrinol. (1986) 25:561-572.
111. KOGA M, NAKAO H, ARAO M et al.: Demonstration of specific dopamine receptors on human pituitary adenomas. Acta Endocrinol. (1987) 114:595-602.
112. 2 receptors. Neurosurgery (1989) 25:948-950.
113. KWEKKEBOOM DJ, LAMBERTS SWJ: Long-term treatment with dopamine agonist CV 205-502 of patients with clinically non-functioning, gonadotroph, or a-subunit secreting pituitary adenoma. Clin. Endocrinol. (1992) 36:171-176.
114. 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J. Clin. Endocrinol. Metab. (1998) 83:248-252.
115. 123I-Methoxybenzamide. Clin Endocrinol (2000). (In Press).
116. SCILLITANI A, DICEMBRINO F, DI FAZIO P et al.: In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. J. Clin. Endocrinol. Metab. (1995) 80:2523-2525.
117. 2 receptor radioligand. Clin. Endocrinol. (1996) 45:755-767.
118. 2 receptors imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas. Eur. J. Nucl. Med. (1999) 26:46-50.
119. 2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with TSH/PRL-producing pituitary macroadenoma. Eur. J. Nucl. Med. (1993) 20:555-561.
120. 2 receptor imaging in pituitary adenomas using Iodine-123-Epidepride and SPECT. J. Nucl. Med. (1996) 37:1931-1937.
121. 2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain. J. Comp. Neurol. (1998) 21:353-371.
122. SONINO N, BOSCARO M: Medical therapy for Cushing's disease. In: Advances in Pituitary Tumour Therapy. Molitch ME (Ed.), (1999):211-222.
123. KRIEGER DT: Physiopathology of Cushing's disease. Endocr. Rev. (1983) 4:22-43-
124. MERCADO-ASIS LB, YASUDA K, MURAYAMA M et al.: Beneficial effects of high daily dose bromocriptine in Cushing's disease. Endocrinol. Jpn. (1992) 39:385-395.
125. YIN D, KONDO S, TAKEUCHI J, MORIMURA T: Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Lett. (1994) 339:73-75.
126. BERWAERTS J, VERHELST J, MAHLER C, ABS R: Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol. Endocrinol. (1999)13:175-182.
127. DORNHORST A, JENKINS JS, LAMBERTS SWJ et al.: The evaluation of sodium valproate in the treatment of Nelson's syndrome. J. Clin. Endocrinol. Metab. (1983) 56:985-991.
128. LAMBERTS SWJ, BIRKENHAGER JC: Bromocriptine in Nelson's syndrome and Cushing's disease. Lancet (1976) 2:811.
129. LAMBERTS SWJ, KLIJN JGM, DE QUIJADA M et al.: The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. J. Clin. Endocrinol. Metab. (1980) 51:307-311.
130. WHITEHEAD HM, BEACOM R, SHERIDAN B, ATKINSON AB: The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy. Clin. Endocrinol. (1990) 32:193-201.
131. PIVONELLO R, FAGGIANO A, DI SALLE F, FILIPPELLA M, LOMBARDI G, COLAO A: Complete remission of Nelsons' syndrome after 1 year treatment with cabergoline: a case report. J. Endocrinol. Invest. (1999) 22:860-865.
132. TURNER TH, COOKSON JC, WASS JAH, DRURY PL, PRICE PA, BESSER GM: Psychotic reactions during treatment of pituitary tumours with dopaminc agonist. Br. Med. J. (1984) 289:1101-1103.
133. BHATT MH, KEENAN SP, FLEETHAM JA et al.: Pleuropulmonary disease associated with dopamine agonist therapy. Ann. Neurol. (1991) 30:613-616.
134. FRANS E, DOM R, DEMEDTS M: Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur. Respir. J. (1992) 5:263-265.
135. LING LH, AHLSKOG JE, MUNGER TM, LIMPER AH, OH JK: Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin. Proc. (1999) 74:371-375.
136. LIUZZI A, OPPIZZI G: Microprolactinomas: why requiem for surgery? J. Endocrinol. Invest. (1996) 19:196-198. The indications for surgery in microprolactinomas are likely underestimated as underlined in this brief paper.
137. VAN'T VERLAAT JW, CHROUGHS RJ: Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin. Endocrinol. (1991) 34:175-178.
138. FAGLIA G: Should dopamine agonists treatment for prolactinomas be life-long? Clin. Endocrinol. (1991) 34:173-174.
139. DISARNO A, LANDI ML, MARZULLO P et al:. The effect of quinagolide and cabergoline, two selective dopamine receptor type-2 agonists, in the treatment of prolactinomas. Clin. Endocrinol. (2000). (In Press).